Changes in Hong Kong stocks | Zhaoyan Pharmaceutical (06127) fell by more than 11%, and the company issued a risk warning announcement, and the price increase of experimental monkeys contributed to the vast majority of net profit

The Zhitong Finance App learned that Zhaoyan New Pharmaceutical (06127) fell by more than 11%. As of press release, it fell 9.76% to HK$23.3, with a turnover of HK$185 million.

According to the news, Zhaoyan Pharmaceutical announced that the cumulative deviation value of the closing price increase of the company's stock over three consecutive trading days was more than 20%. The company's stock price increased significantly in the short term. There is a risk of excessive market sentiment and irrational hype. The transaction risk is extremely high, and there is a risk that the stock price will fall at any time. In addition, the fair value of the company's biological assets is affected by various uncertainties, and there is a high risk of value fluctuations.

Zhaoyan Pharmaceutical recently released Yingxi. It is expected that the first half of the year's revenue will be about 669 million yuan to 739 million yuan, an increase of about 0% to 10.5% over the previous year; net profit to the mother will be 600 million yuan to 900 million yuan, an increase of 884.9% to 1377.4% over the previous year. The performance explosion was not due to a sharp improvement in order profits from the main security assessment business, but from the appreciation of the company's experimental monkey assets. Changes in the fair value of biological assets contributed 703 million yuan to 777 million yuan in net profit during the period.